Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

Subcribe to Pα+
Visit the Pα+ Dashboard

The latest

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in PPD; America’s 10 Million Microdosers

January 22, 2026

FDA’s Farchione Says Psychedelic INDs Now “a Third” of Her Workload; NIDA’s Volkow Questions Schedule I Placement • Ipsos/Psychedelic Alpha Poll Probes Americans’ Attitudes Towards Psychedelics • RAND Estimates 10 Million U.S. Adults Microdosed Last Year • Reunion Targets Single Phase 3 Path in PPD; Releases Additional Phase 2 Data • MindMed Rebrands to Definium, Launches LSD Education Push • Interview: Independent Psychedelic Evidence Assessment Working Group • New Jersey Governor Signs $6M Psilocybin Pilot Program Into Law • and more…

Psychedelic Funding, Public Markets, and M&A in 2025

January 20, 2026

We have tracked every investment for the past ten years. Each year, we provide a review of the previous year’s psychedelics fundraising activity, public markets, and M&A. Here, we explore Q4 and full year 2025 via data visualisation and commentary.

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

January 15, 2026

As we head into what many expect to be a pivotal year, we asked people from across the psychedelics field what they are excited about, concerned by, and hoping to gain clarity on in 2026. What emerges is a picture of tempered anticipation: acceptance of the importance of the year ahead is paired with a sober realism about what pivotal data, regulatory decisions, and access pathways may or may not resolve.

Load more

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Subcribe to Pα+

Pα+ Library: Bifurcated Scheduling

December 6, 2023

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

November 15, 2023

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic Practitioner

The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.

The Psychedelic Practitioner Issue 2: Preparation

December 11, 2025

The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into the science and practice of psychedelic preparation through interviews, research reviews, and practitioner perspectives.

The Psychedelic Practitioner: Issue 1

October 9, 2025

The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.

Load more